CoChat

Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.

Hurwitz, Herbert, Raghav, Kanwal Pratap Singh, Burris, Howard A., Kurzrock, Razelle, Sweeney, Christopher, Meric-Bernstam, Funda, Vanderwalde, Ari M., Spigel, David R., Bose, Ron, Fakih, Marwan, Swanton, Charles, Guo, Shuangli, Bernaards, Coen, Beattie, Mary Stanley, Sommer, Nicolas, Hainsworth, John D. · 2017 · Journal of Clinical Oncology
Cited by 38

The DOI matches its Crossref record.

Abstract

676 Background: Among recent advances in precision medicine, HER2 has emerged as a potential therapeutic target for advanced colon cancer. MyPathway is a multi-basket study evaluating the efficacy and safety of targeted therapies in non-indicated tumor types harboring relevant genetic alterations. We present updated data for an expanded cohort of patients with HER2-amplified/overexpressed mCRC receiving HER2-targeted therapy with pertuzumab + trastuzumab. Methods: MyPathway (NCT02091141) is a multicenter, open-label, phase IIA study. Patients in this analysis had treatment-refractory HER2-amplified/overexpressed mCRC by gene sequencing, FISH, or IHC. Patients received standard doses of pertuzumab + trastuzumab until disease progression or unacceptable toxicity. The primary endpoint is investigator-assessed overall response rate. The cutoff date was July 31, 2016. Results: Of 34 patients with mCRC enrolled, 32 have had ≥1 tumor assessment. At a median follow-up of 5.2 (range 0.7–18.3) months from treatment initiation, 12 patients had partial responses (PR), with stable disease (SD) for >4 months in 3 additional patients (Table). The safety profiles were consistent with the product labels. Conclusions: Interim data show that HER2-targeted therapy with pertuzumab + trastuzumab, a chemotherapy-free regimen, is active in heavily pretreated HER2-amplified/overexpressed mCRC. The ORR was 37.5%, responses were durable (median 11.1 months), and the CBR was 46.9%. Accrual to MyPathway is ongoing. Clinical trial information: NCT02091141. [Table: see text]

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.35.4_suppl.676

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 38

Metadata

Authors
Hurwitz, H., Raghav, K. P. S., Burris, H. A., Kurzrock, R., Sweeney, C., Meric-Bernstam, F., Vanderwalde, A. M., Spigel, D. R., Bose, R., Fakih, M., Swanton, C., Guo, S., Bernaards, C., Beattie, M. S., Sommer, N., & Hainsworth, J. D.
Venue
Journal of Clinical Oncology
Published
2017-02-01
Volume
35
Issue
4_suppl
Pages
676-676
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2598448479
Cited by
38
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. https://app.cochat.ai/papers/10.1200/jco.2017.35.4_suppl.676
The paper
Hurwitz, H., Raghav, K. P. S., Burris, H. A., Kurzrock, R., Sweeney, C., Meric-Bernstam, F., Vanderwalde, A. M., Spigel, D. R., Bose, R., Fakih, M., Swanton, C., Guo, S., Bernaards, C., Beattie, M. S., Sommer, N., & Hainsworth, J. D. (2017). Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.35.4_suppl.676

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.